ITGB4 and neoplasm: Functionally, we established via cytotoxicity, serum binding, and complement assays that ITGB4-DC vaccination, combined with anti-PD-L1 immunotherapy, induced cytotoxic splenic T cells and serum antibodies capable of mediating the binding and killing of both bulk tumor cells and ALDHhigh CSCs.